One of these treatment modalities is TM-ILP (TNF-melphalan-based isolated limb perfusion), which has developed into a successful treatment option for primarily non-resectable soft-tissue sarcoma of the extremities. This evidence concerns the gene XIAP and soft tissue sarcoma.